Drug Profile
ONT 10
Alternative Names: BGLP-40; L-BGLP40Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Biomira
- Developer Celldex Therapeutics Inc; Oncothyreon
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Breast cancer; Ovarian cancer; Solid tumours
Most Recent Events
- 03 May 2018 Immunovaccine is now called IMV
- 05 Nov 2015 Discontinued - Phase-I for Breast cancer (Combination therapy, Late-stage disease) in USA (SC)
- 05 Nov 2015 Discontinued - Phase-I for Ovarian cancer (Combination therapy, Late-stage disease) in USA (SC)